BenevolentAI, one of the world’s largest private AI companies, in partnership with the Association of Medical Research Charities (“AMRC”) announced today it has created a new award, the BenevolentAI Award, to help charities accelerate their medical research and potentially develop new treatments and therapies using artificial intelligence.
BenevolentAI, one of the world’s largest private AI companies, today announced it has hired Dr Ian Churcher as its new VP of Drug Discovery & Preclinical Development of its bioscience subsidiary BenevolentBio.
BenevolentAI, one of the world’s largest private AI companies, today announced it is expanding its footprint in the United States by opening an office in New York City and has made two significant hires - Keith Hall, from Google, and Daniel Neil, from the Institute of Neuroinformatics, that will form the foundation of the new New York BenevolentAI team.
One of the world’s largest private AI companies – BenevolentAI, that develops and applies artificial intelligence for scientific innovation, today announced it has hired Dr Nathan Brown BSc (Hons) FRSC, as its new Head of Cheminformatics following the promotion of Mark Davies from Head of Cheminformatics at BenevolentAI to VP Biomedical Informatics earlier in the year.
Sheffield and London, UK - 25 May 2017. The Sheffield Institute for Translational Neuroscience (SITraN), part of the University of Sheffield and one of the world’s leading centres for research into Motor Neurone Disease, Alzheimer’s and Parkinson’s Disease, today announced that its research into a drug candidate discovered by British artificial intelligence firm BenevolentAI has delivered positive results.
London, 11 April 2017 – BenevolentAI, a British artificial intelligence company, today announced that it has partnered with MRC Technology (“MRCT”), a medical research charity, to explore drug discovery initiatives in the field of small molecules and antibodies.
Revealed at the 2017 CB Insights Innovation Summit, Santa Barbara, California